EUVIMEDEUVIMED entdecken
Crossref

Development of hyaluronic acid–anchored polycaprolactone nanoparticles for efficient delivery of PLK1 siRNA to breast cancer

Dolly Jain, Awesh K Yadav

Drug Delivery and Translational Research · 2023

DOI: 10.1007/s13346-022-01288-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2023. Verfasst von Dolly Jain und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Bhagyoday Tirth Pharmacy College, Sagar, 470002, Madhya Pradesh, India. Hauptthemen laut MEDLINE: Breast Neoplasms, Nanoparticles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: DBT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PlK1 has a significant role in the development of breast cancer. Thus, silencing of PlK1 gene may arrest the growth of breast cancer. However, the in vivo stability of PlK1 siRNA after injection remains a challenge to target the specific site. The delivery of siPlK1 RNA via viral vector and amine group-terminated dendrimer is associated with immune reaction and cellular cytotoxicity. Thus, in the present study, hyaluronic acid-functionalized and -thiolated polycaprolactone nanoparticles (SH-HPP NPs) were developed for enhancing the targeting capabilities of siRNA towards human breast cancer cells. NPs displayed size in the range of 180-217 nm, and with sustain and pH-dependent release of siRNA up to 120 h. The in vitro treatments with siRNA-containing NPs showed the high number of necrotic cells and the cell cycle arrest at the G2/M phase. The gene expression analysis depicts the decrease of endogenous PLK1 siRNA expression on MCF-7 cells upon PLK1 NPs treatment. In vitro cytotoxicity experiments demonstrated effective anticancer properties against MCF-7. Finally, in vivo results showed that substantial tumor inhibition was achieved with PLK1 siRNA-containing SH-HPP NPs in comparison of the control group. Hence, HPP NPs have enormous potential for the selective delivery of siRNA, i.e., breast cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNanoparticlesFemaleHumansCell Line, TumorHyaluronic AcidRNA, Small InterferingPolo-Like Kinase 1Polyesters

Stichwörter der Autor:innen

Breast cancerCD44 receptorsGene silencingHyaluronic acidNanoparticlesPLK1 siRNA

Substanzen

Hyaluronic AcidRNA, Small InterferingPolo-Like Kinase 1polycaprolactonePolyesters

Autor:innen und Institutionen

  • Department of Pharmaceutics, Bhagyoday Tirth Pharmacy College, Sagar, 470002, Madhya Pradesh, India.
  • Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Uttar Pradesh, Raebareli, 229010, India. awesh.yadav@niperraebareli.edu.in.

Förderung

  • DBT

Zitieren

APA

Jain, D., & Yadav, A. K. (2023). Development of hyaluronic acid–anchored polycaprolactone nanoparticles for efficient delivery of PLK1 siRNA to breast cancer. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-022-01288-2

Vancouver

Jain D, Yadav AK. Development of hyaluronic acid–anchored polycaprolactone nanoparticles for efficient delivery of PLK1 siRNA to breast cancer. Drug Delivery and Translational Research. 2023. doi:10.1007/s13346-022-01288-2

BibTeX
@article{Jain2023,
  author = {Jain, Dolly and Yadav, Awesh K},
  title = {Development of hyaluronic acid–anchored polycaprolactone nanoparticles for efficient delivery of PLK1 siRNA to breast cancer},
  journal = {Drug Delivery and Translational Research},
  year = {2023},
  doi = {10.1007/s13346-022-01288-2}
}
Kostenlos starten →